ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations

Stock News04-30

ASCLETIS-B (01672) rose more than 3% during the morning trading session. At the time of writing, the stock was up 2.06%, trading at HK$16.85 with a turnover of HK$7.3672 million. The company announced that it will present multiple projects via posters at the American Diabetes Association (ADA) 2026 Scientific Sessions, scheduled for June 5-8 in New Orleans, Louisiana. The presentations will include preclinical data for ASC39, an oral small-molecule amylin receptor agonist with selectivity and potency, similar to eloralintide, for the treatment of obesity. This presentation has been selected as a late-breaking poster. Notably, on April 27, ASCLETIS-B announced that the U.S. Phase II study for its core product, the oral small-molecule GLP-1R agonist ASC30 for type 2 diabetes, has successfully completed patient enrollment. This marks the product's second major indication following obesity, representing a key step in the company's commercialization strategy within the metabolic disease field.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102994678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-30 12:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102994678","market":"sg","top_or_hot":-1,"title":"ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations","media":"Stock News","content":"<p>ASCLETIS-B (01672) rose more than 3% during the morning trading session. At the time of writing, the stock was up 2.06%, trading at HK$16.85 with a turnover of HK$7.3672 million. The company announced that it will present multiple projects via posters at the American Diabetes Association (ADA) 2026 Scientific Sessions, scheduled for June 5-8 in New Orleans, Louisiana. The presentations will include preclinical data for ASC39, an oral small-molecule amylin receptor agonist with selectivity and potency, similar to eloralintide, for the treatment of obesity. This presentation has been selected as a late-breaking poster. Notably, on April 27, ASCLETIS-B announced that the U.S. Phase II study for its core product, the oral small-molecule GLP-1R agonist ASC30 for type 2 diabetes, has successfully completed patient enrollment. This marks the product's second major indication following obesity, representing a key step in the company's commercialization strategy within the metabolic disease field.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASCLETIS-B Shares Climb Over 3% in Morning Session on Upcoming ADA 2026 Conference Presentations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-30 12:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ASCLETIS-B (01672) rose more than 3% during the morning trading session. At the time of writing, the stock was up 2.06%, trading at HK$16.85 with a turnover of HK$7.3672 million. The company announced that it will present multiple projects via posters at the American Diabetes Association (ADA) 2026 Scientific Sessions, scheduled for June 5-8 in New Orleans, Louisiana. The presentations will include preclinical data for ASC39, an oral small-molecule amylin receptor agonist with selectivity and potency, similar to eloralintide, for the treatment of obesity. This presentation has been selected as a late-breaking poster. Notably, on April 27, ASCLETIS-B announced that the U.S. Phase II study for its core product, the oral small-molecule GLP-1R agonist ASC30 for type 2 diabetes, has successfully completed patient enrollment. This marks the product's second major indication following obesity, representing a key step in the company's commercialization strategy within the metabolic disease field.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1102994678","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102994678","pubTimestamp":1777522097,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ASCLETIS-B (01672) rose more than 3% during the morning trading session. At the time of writing, the stock was up 2.06%, trading at HK$16.85 with a turnover of HK$7.3672 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","01477":"欧康维视生物-B","BK1515":"抗疫概念","01672":"歌礼制药-B","BK1191":"制药","BK1161":"生物科技","BK1574":"生物医药B类股","BK4588":"碎股"},"translate_title":"由于即将举行的ADA 2026会议演讲，歌礼-B股价在早盘上涨超过3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"01477":1,"01672":1},"content_text":"ASCLETIS-B (01672) rose more than 3% during the morning trading session. At the time of writing, the stock was up 2.06%, trading at HK$16.85 with a turnover of HK$7.3672 million. The company announced that it will present multiple projects via posters at the American Diabetes Association (ADA) 2026 Scientific Sessions, scheduled for June 5-8 in New Orleans, Louisiana. The presentations will include preclinical data for ASC39, an oral small-molecule amylin receptor agonist with selectivity and potency, similar to eloralintide, for the treatment of obesity. This presentation has been selected as a late-breaking poster. Notably, on April 27, ASCLETIS-B announced that the U.S. Phase II study for its core product, the oral small-molecule GLP-1R agonist ASC30 for type 2 diabetes, has successfully completed patient enrollment. This marks the product's second major indication following obesity, representing a key step in the company's commercialization strategy within the metabolic disease field.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102994678","isCrawlerRequest":true}